Monopar commenced a Phase 1b open-label dose escalation clinical trial in the US in Q3 2021 in advanced soft tissue sarcoma (ASTS) patients. Following completion of the Phase 1b trial, Monopar anticipates conducting a randomized, Phase 2 clinical trial evaluating camsirubicin head-to-head against doxorubicin in the 1st line treatment setting for ASTS. The primary endpoint of the trial is planned to be progression-free survival, with secondary endpoints that will include response rate and overall survival. Camsirubicin has been granted Orphan Drug Designation in both the US and EU.